Kerala Ayurveda Share Price

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	36.64	34.09	36.54	38.08	32.05
Total Income Growth (%)	7.49	-6.71	-4.05	18.84	2.19
Total Expenses	43.53	35.62	40.78	34.45	43.38
Total Expenses Growth (%)	22.19	-12.65	18.38	-20.59	31.31
EBIT	-6.88	-1.53	-4.24	3.63	-11.33
EBIT Growth (%)	-	-	-216.73	-	-
Profit after Tax (PAT)	-7.76	-4.45	-6.34	1.99	-15.54
PAT Growth (%)	-	-	-418.72	-	-
EBIT Margin (%)	-18.79	-4.50	-11.61	9.54	-35.37
Net Profit Margin (%)	-21.18	-13.04	-17.35	5.22	-48.48
Basic EPS (₹)	-5.83	-3.69	-7.23	1.92	-13.68

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	29.27	23.04	23.55	27.56	23.72
Total Income Growth (%)	27.03	-2.15	-14.58	16.21	21.74
Total Expenses	36.29	24.71	26.87	24.22	31.80
Total Expenses Growth (%)	46.88	-8.05	10.95	-23.83	65.06
EBIT	-7.03	-1.67	-3.33	3.34	-8.08
EBIT Growth (%)	-	-	-199.42	-	-3,757.56
Profit after Tax (PAT)	-7.93	-3.47	-5.40	2.07	-11.86
PAT Growth (%)	-	-	-361.26	-	-
EBIT Margin (%)	-24.01	-7.24	-14.12	12.13	-34.05
Net Profit Margin (%)	-27.11	-15.07	-22.94	7.50	-50.02
Basic EPS (₹)	-6.25	-3.03	-4.58	1.73	-9.86

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	145.36	122.15	108.37	93.70	80.70
Total Revenue Growth (%)	19.00	12.71	15.66	16.11	29.77
Total Expenses	161.72	134.39	107.10	97.09	78.69
Total Expenses Growth (%)	20.34	25.48	10.31	23.38	14.17
Profit after Tax (PAT)	-16.56	-13.96	-1.53	-0.90	2.36
PAT Growth (%)	-	-	-	-138.13	-
Operating Profit Margin (%)	-6.88	-6.77	5.31	1.52	10.61
Net Profit Margin (%)	-12.62	-11.60	-1.41	-0.96	2.93
Basic EPS (₹)	-13.53	-11.60	-1.42	-0.51	0.26

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	103.42	77.86	73.31	63.36	56.10
Total Revenue Growth (%)	32.83	6.21	15.70	12.93	29.35
Total Expenses	119.37	91.34	72.88	63.82	54.87
Total Expenses Growth (%)	30.68	25.33	14.19	16.31	9.85
Profit after Tax (PAT)	-14.74	-13.78	-0.27	2.89	0.89
PAT Growth (%)	-	-	-109.38	224.98	-
Operating Profit Margin (%)	-10.14	-13.15	5.81	6.28	12.76
Net Profit Margin (%)	-17.24	-18.95	-0.37	4.56	1.59
Basic EPS (₹)	-12.21	-11.45	-0.28	3.09	1.17

All figures in Rs Cr, unless mentioned otherwise

Insights

Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 19.0% outperformed its 3 year CAGR of 15.59%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 5.6% of its operating revenues towards interest expenses and 51.13% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	138.42	128.76	140.71	114.72	110.24
Total Assets Growth (%)	7.50	-8.49	22.65	4.06	-3.71
Total Liabilities	123.54	115.87	105.57	106.84	102.30
Total Liabilities Growth (%)	6.61	9.75	-1.19	4.44	-6.39
Total Equity	14.89	12.89	35.13	7.88	7.94
Total Equity Growth (%)	15.50	-63.31	345.83	-0.77	52.62
Current Ratio (x)	0.47	0.46	1.49	0.66	0.61
Total Debt to Equity (x)	7.27	6.95	2.10	12.99	11.43
Contingent Liabilities	0.00	-	-	-	5,000.00

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	139.66	118.89	124.05	97.52	91.70
Total Assets Growth (%)	17.47	-4.16	27.20	6.35	-4.71
Total Liabilities	103.51	93.76	81.68	82.99	80.42
Total Liabilities Growth (%)	10.40	14.79	-1.58	3.20	-6.69
Total Equity	36.15	25.13	42.38	14.53	11.28
Total Equity Growth (%)	43.85	-40.70	191.67	28.81	12.35
Current Ratio (x)	0.93	0.86	2.02	0.65	0.50
Total Debt to Equity (x)	1.94	2.15	1.41	4.30	5.44
Contingent Liabilities	0.00	-	-	-	5,000.00

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	-24.13	4.83	2.03	9.86	-0.50
Net Cash used in Investing Activities	-5.48	-14.77	-1.26	-7.22	-1.91
Net Cash flow from Financing Activities	32.39	-9.48	17.64	-2.32	-13.35
Net Cash Flow	2.77	-19.42	18.42	0.32	-15.76
Closing Cash & Cash Equivalent	0.80	3.39	22.79	3.20	2.80
Closing Cash & Cash Equivalent Growth (%)	-76.35	-85.13	612.63	14.14	-84.90
Total Debt/ CFO (x)	-3.35	13.65	33.24	7.35	-139.25

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	-25.05	2.28	-4.22	9.12	8.75
Net Cash used in Investing Activities	-3.19	-6.48	-2.18	-5.32	0.83
Net Cash flow from Financing Activities	29.86	-11.93	21.15	-3.38	-10.52
Net Cash Flow	1.62	-16.13	14.75	0.41	-0.94
Closing Cash & Cash Equivalent	-3.38	0.36	16.48	0.55	0.13
Closing Cash & Cash Equivalent Growth (%)	-1,035.33	-97.81	2,919.63	312.78	-87.67
Total Debt/ CFO (x)	-2.80	23.78	-14.17	6.85	7.01

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 5.48 cr for investing activities which is an YoY decrease of 62.87%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	-148.85	-147.03	-4.74	-16.14	38.65
Return on Capital Employed (%)	-23.13	-19.97	5.71	2.25	17.07
Return on Assets (%)	-11.96	-10.84	-1.08	-0.78	2.14
Interest Coverage Ratio (x)	-0.48	-0.78	1.59	0.53	1.49
Asset Turnover Ratio (x)	0.98	0.89	0.84	0.83	0.54
Price to Earnings (x)	-12.09	-30.30	-208.33	-98.04	34.97
Price to Book (x)	18.00	44.52	9.77	15.79	13.50
EV/EBITDA (x)	-78.85	-153.92	51.15	62.93	15.56
EBITDA Margin (%)	-2.69	-2.63	6.56	2.71	12.10

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	-40.78	-54.84	-0.63	19.89	7.88
Return on Capital Employed (%)	-18.52	-25.45	4.28	6.67	15.98
Return on Assets (%)	-10.55	-11.59	-0.21	2.96	0.97
Interest Coverage Ratio (x)	-0.70	-1.89	1.31	1.04	1.34
Asset Turnover Ratio (x)	0.66	0.60	0.66	0.67	0.59
Price to Earnings (x)	-13.59	-30.67	-1,250.00	30.49	93.46
Price to Book (x)	5.54	16.82	7.42	6.06	7.32
EV/EBITDA (x)	-52.91	-64.24	71.22	32.46	18.22
EBITDA Margin (%)	-5.94	-10.20	6.86	7.29	14.13

Insights

Losing Shareholder's Money
Company has reported a negative ROE for 3 consecutive years. (Source: Consolidated Financials)

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Kerala Ayurveda	-14.95	16.62	-148.85	-23.13	-11.96	15.59	-6.88	-12.44	-13.53	0.47	7.27	-3.35
Abbott India	35.70	11.61	32.50	41.87	23.87	9.36	30.36	22.39	730.36	2.55	0.00	0.00
GSK Pharma	38.68	17.67	45.68	54.54	23.95	5.71	36.32	27.10	61.15	2.03	0.00	0.00
AstraZeneca	113.92	24.48	21.48	26.00	9.42	30.47	11.51	8.24	75.01	1.77	0.00	0.00
Pfizer	28.31	22.69	33.24	22.93	27.21	2.32	28.27	40.85	100.38	5.04	0.00	0.00
Add More

Annual Ratios (%)

Choose from Peers

Sanofi Consumer Healthcare India Ltd.
P&G Health
Sanofi India
Novartis India
Decipher Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Kerala Ayurveda Stock Performance	-2.68	-9.84	-20.79	-16.47	-54.67	54.82	256.07
Abbott India Stock Performance	-0.55	-5.24	2.68	-0.72	-17.02	24.85	62.40
GSK Pharma Stock Performance	1.40	-2.16	-2.53	-9.02	-20.74	83.58	61.76
AstraZeneca Stock Performance	1.64	2.34	1.07	-4.02	7.56	167.32	126.60
Pfizer Stock Performance	-1.33	-4.64	-7.21	-9.47	-10.23	16.99	-14.64
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	46,27,026	35.61 %	2.46
Pledge	9,41,667	20.35 %	-3.20
FII	21,679	0.17 %	-0.04
DII	2,976	0.02 %	0.00
MF	2,976	0.02 %	0.00
Others	83,43,404	64.19 %	-2.42

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	35.61	33.14	33.14	37.83
Pledge	20.35	23.56	23.56	20.69
FII	0.17	0.22	0.00	0.00
DII	0.02	0.02	0.02	0.02
Mutual Funds	0.02	0.02	0.02	0.02
Others	64.19	66.62	66.84	62.15

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Audited Results
May 20, 2026
Board Meeting
Others
Mar 23, 2026
General Meeting
-
Feb 20, 2026

Board Meetings

Announced on	Meeting on
May 20, 2026	May 25, 2026
Audited Results
Mar 23, 2026	Mar 25, 2026
Others
Feb 09, 2026	Feb 12, 2026
Quarterly Results & Preferential issue
Nov 10, 2025	Nov 14, 2025
Quarterly Results
Jul 15, 2025	Jul 18, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
Sep 02, 2002 Sep 05, 2002 0%
Aug 05, 1999 - -
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Feb 20, 2026 Mar 14, 2026
-
Dec 19, 2025 Jan 21, 2026
-
Sep 11, 2025 Sep 26, 2025
-
Jul 23, 2025 Aug 24, 2025
-
May 28, 2025 Jun 18, 2025
-

Announced on	Ex-Date	Dividend%
Sep 02, 2002	Sep 05, 2002	0%
Aug 05, 1999	-	-

Announced on	Meeting on
Feb 20, 2026	Mar 14, 2026
-
Dec 19, 2025	Jan 21, 2026
-
Sep 11, 2025	Sep 26, 2025
-
Jul 23, 2025	Aug 24, 2025
-
May 28, 2025	Jun 18, 2025
-

About Kerala Ayurveda

Kerala Ayurveda Ltd., incorporated in the year 1992, is a Small Cap company (having a market cap of Rs 247.56 Crore) operating in Pharmaceuticals sector.

Kerala Ayurveda Ltd. key Products/Revenue Segments include Ayurvedic Medicines, Sale of services and Other Operating Revenue for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 36.64 Crore, up 7.49 % from last quarter Total Income of Rs 34.09 Crore and up 14.34 % from last year same quarter Total Income of Rs 32.05 Crore. Company has reported net profit after tax of Rs -7.40 Crore in latest quarter.

The company’s top management includes Mr.Ramesh Vangal, Mr.Vivek Sunder, Dr.Kunjupanicker Anilkumar, Dr.Kodikannath Jayarajan, Mr.Utkarsh Singh, Mr.Kshiti Ranjan Das, Mr.Rajesh Sharma, Mr.Samir Dhawan, Ms.Shilpa Kiran Gududur, Mr.K T George, Ms.Priyanka Gangwar. Company has Maharaj Rajan & Mathew as its auditors. As on 31-03-2026, the company has a total of 1.30 Crore shares outstanding.

Kerala Ayurveda Share Price Today is Rs. 190.50. On previous day, the Kerala Ayurveda Share Price (NSE) closed at Rs. 192.55, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 35.61% of the stake in Kerala Ayurveda shares, out of which 20.35% was pledged. On the same date, foreign institutional investors' (FII) holdings of Kerala Ayurveda stocks was 0.17% as compared to 0.22% in Dec 2025 with decrease of 0.05%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.02% as compared to 0.02% in Dec 2025 with decrease of 0.0%. Out of the total DII holdings in Kerala Ayurveda shares 0.02% was held by mutual funds. The rest including public held is 64.2%. Kerala Ayurveda stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Kerala Ayurveda Dividend: Ever since 1992, Kerala Ayurveda dividends has been paid out around 2 times. As on 22 Jun, 2026, 03:40 PM IST, The overall dividend yield for Kerala Ayurveda stands at 0.0%. The last dividend paid was on null (Rs. null). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. -12.74.

Kerala Ayurveda Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 36.64 Cr. of sales and 7.49% of quarterly net profit, there have been multiple ups and downs in the Kerala Ayurveda stock prices in the past few weeks. For example, Kerala Ayurveda stock price on 12th of June 2026 was around Rs. 173.75. Kerala Ayurveda share price now stands at an average of Rs. 190.50. Judging by last week's performance, stock is in up trend.

Kerala Ayurveda has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Kerala Ayurveda share.

Historical Prices and Performance:
Kerala Ayurveda, incorporated in 1992 is a Small Cap company (with a market cap of Rs. 253.73) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Kerala Ayurveda stock was -148.85%, -147.03%, -4.74%, -16.14% and 38.65% respectively.
The Kerala Ayurveda share gave a 3 year return of 75.66% as compared to Nifty 50 which gave a return of 28.03%.
Kerala Ayurveda announced 0.0% final dividend on null.

Key Metrics:
PE Ratio of Kerala Ayurveda is -15.11
Prices/Sales Ratio of Kerala Ayurveda is 1.53
Price/Book Ratio of Kerala Ayurveda is 16.8

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. The PE ratio and PB Ratio of the company are among its competitors stand at -15.11 and 16.8 respectively.

Leadership of Kerala Ayurveda :
Priyanka Gangwar is Co. Secretary & Compl. Officer
K T George is Chief Financial Officer
Vivek Sunder is Chief Executive Officer
Ramesh Vangal is Chairman
Kunjupanicker Anilkumar is Whole Time Director
Kodikannath Jayarajan is Non Executive Director
Utkarsh Singh is Non Executive Director
Rajesh Sharma is Independent Director
Shilpa Kiran Gududur is Independent Director
Samir Dhawan is Independent Director
Kshiti Ranjan Das is Independent Director
Priyanka Gangwar is Co. Secretary & Compl. Officer
K T George is Chief Financial Officer
Vivek Sunder is Chief Executive Officer
Ramesh Vangal is Chairman
Kunjupanicker Anilkumar is Whole Time Director
Kodikannath Jayarajan is Non Executive Director
Utkarsh Singh is Non Executive Director
Rajesh Sharma is Independent Director
Shilpa Kiran Gududur is Independent Director
Samir Dhawan is Independent Director
Kshiti Ranjan Das is Independent Director
Priyanka Gangwar is Co. Secretary & Compl. Officer
K T George is Chief Financial Officer
Vivek Sunder is Chief Executive Officer
Ramesh Vangal is Chairman
Kunjupanicker Anilkumar is Whole Time Director
Kodikannath Jayarajan is Non Executive Director
Utkarsh Singh is Non Executive Director
Rajesh Sharma is Independent Director
Shilpa Kiran Gududur is Independent Director
Samir Dhawan is Independent Director
Kshiti Ranjan Das is Independent Director
Priyanka Gangwar is Co. Secretary & Compl. Officer
K T George is Chief Financial Officer
Vivek Sunder is Chief Executive Officer
Ramesh Vangal is Chairman
Kunjupanicker Anilkumar is Whole Time Director
Kodikannath Jayarajan is Non Executive Director
Utkarsh Singh is Non Executive Director
Rajesh Sharma is Independent Director
Shilpa Kiran Gududur is Independent Director
Samir Dhawan is Independent Director
Kshiti Ranjan Das is Independent Director
Priyanka Gangwar is Co. Secretary & Compl. Officer
K T George is Chief Financial Officer
Vivek Sunder is Chief Executive Officer
Ramesh Vangal is Chairman
Kunjupanicker Anilkumar is Whole Time Director
Kodikannath Jayarajan is Non Executive Director
Utkarsh Singh is Non Executive Director
Rajesh Sharma is Independent Director
Shilpa Kiran Gududur is Independent Director
Samir Dhawan is Independent Director
Kshiti Ranjan Das is Independent Director
Priyanka Gangwar is Co. Secretary & Compl. Officer
K T George is Chief Financial Officer
Vivek Sunder is Chief Executive Officer
Ramesh Vangal is Chairman
Kunjupanicker Anilkumar is Whole Time Director
Kodikannath Jayarajan is Non Executive Director
Utkarsh Singh is Non Executive Director
Rajesh Sharma is Independent Director
Shilpa Kiran Gududur is Independent Director
Samir Dhawan is Independent Director
Kshiti Ranjan Das is Independent Director
Priyanka Gangwar is Co. Secretary & Compl. Officer
K T George is Chief Financial Officer
Vivek Sunder is Chief Executive Officer
Ramesh Vangal is Chairman
Kunjupanicker Anilkumar is Whole Time Director
Kodikannath Jayarajan is Non Executive Director
Utkarsh Singh is Non Executive Director
Rajesh Sharma is Independent Director
Shilpa Kiran Gududur is Independent Director
Samir Dhawan is Independent Director
Kshiti Ranjan Das is Independent Director
Priyanka Gangwar is Co. Secretary & Compl. Officer
K T George is Chief Financial Officer
Vivek Sunder is Chief Executive Officer
Ramesh Vangal is Chairman
Kunjupanicker Anilkumar is Whole Time Director
Kodikannath Jayarajan is Non Executive Director
Utkarsh Singh is Non Executive Director
Rajesh Sharma is Independent Director
Shilpa Kiran Gududur is Independent Director
Samir Dhawan is Independent Director
Kshiti Ranjan Das is Independent Director

Industry

Pharma - MNC

Key Indices Listed On

-

Address

VII/415, Athani,Nedumbassery,Aluva, Kerala - 683585

Contact

info@keralaayurveda.biz

http://www.keralaayurveda.biz

PE Ratio(x)	-14.95
EPS - TTM(₹)	-12.74
MCap(₹ Cr.)	247.56
MCap Rank	116
PB Ratio(x)	17.04
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	625.00
52W Low(₹)	150.00
MCap/Sales	1.53
Beta(1 Month)	0.35
BV/Share(₹)	11.46

1 Day	-2.68%
1 Month	-9.82%
3 Months	3.14%
1 Year	-55.33%
3 Years	81.17%
5 Years	230.44%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Kerala Ayurveda Share Price

Key Metrics